Structural simplification: an efficient strategy in lead optimization

The trend toward designing large hydrophobic molecules for lead optimization is often associated with poor drug-likeness and high attrition rates in drug discovery and development. Structural simplification is a powerful strategy for improving the efficiency and success rate of drug design by avoiding “molecular obesity”. The structural simplification of large or complex lead compounds by truncating unnecessary groups can not only improve their synthetic accessibility but also improve their pharmacokinetic profiles, reduce side effects and so on. This review will summarize the application of structural simplification in lead optimization. Numerous case studies, particularly those involving successful examples leading to marketed drugs or drug-like candidates, will be introduced and analyzed to illustrate the design strategies and guidelines for structural simplification.

[1]  L. Weber The application of multi-component reactions in drug discovery. , 2002, Current medicinal chemistry.

[2]  P. Paira,et al.  Discovery of simplified N²-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: efficient synthetic approaches, biological evaluations and molecular docking studies. , 2014, Bioorganic & medicinal chemistry.

[3]  H. Hussain,et al.  Lapachol: An overview , 2007 .

[4]  G. T. Liu Therapeutic effects of biphenyl dimethyl dicarboxylate (DDB) on chronic viral hepatitis B. , 1987, Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College = Chung-kuo i hsueh k'o hsueh yuan, Chung-kuo hsieh ho i k'o ta hsueh hsueh pao.

[5]  György M Keseru,et al.  Hit discovery and hit-to-lead approaches. , 2006, Drug discovery today.

[6]  R. Bosotti,et al.  Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. , 2008, Journal of medicinal chemistry.

[7]  S. Tepper,et al.  Clinical and Preclinical Rationale for CGRP‐Receptor Antagonists in the Treatment of Migraine , 2008, Headache.

[8]  M. Faul,et al.  (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. , 1996, Journal of medicinal chemistry.

[9]  J. Glorioso,et al.  Protocol Optimization for the Production of the Non-Cytotoxic JΔNI5 HSV Vector Deficient in Expression of Immediately Early Genes , 2020, Molecular therapy. Methods & clinical development.

[10]  C. Ghelardini,et al.  Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity. , 2000, Journal of medicinal chemistry.

[11]  James D White,et al.  Morphine, the Proteus of organic molecules. , 2002, Chemical communications.

[12]  Herbert Waldmann,et al.  Highly enantioselective synthesis and cellular evaluation of spirooxindoles inspired by natural products , 2010, Nature Chemistry.

[13]  M. Faul,et al.  Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. , 2003, Bioorganic & medicinal chemistry letters.

[14]  S. Matthews,et al.  Crystal structure of human CDC7 kinase in complex with its activator DBF4 , 2012, Nature Structural &Molecular Biology.

[15]  Alejandra Prieto-Davó,et al.  Antibiotic terpenoid chloro-dihydroquinones from a new marine actinomycete. , 2005, Journal of natural products.

[16]  Shengzheng Wang,et al.  Structural Simplification of Natural Products. , 2019, Chemical reviews.

[17]  A. W. Shaw,et al.  Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). , 2007, Journal of medicinal chemistry.

[18]  Stefan Wetzel,et al.  Interactive exploration of chemical space with Scaffold Hunter. , 2009, Nature chemical biology.

[19]  J. Fudin,et al.  Levorphanol use: past, present and future , 2016, Postgraduate medicine.

[20]  Yaxue Zhao,et al.  Discovery of N-(4-sulfamoylphenyl)thioureas as Trypanosoma brucei leucyl-tRNA synthetase inhibitors. , 2013, Organic & biomolecular chemistry.

[21]  Richard Pazdur,et al.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. , 2007, The oncologist.

[22]  J. Ovádi,et al.  New anti-mitotic drugs with distinct anti-calmodulin activity. , 2006, Mini reviews in medicinal chemistry.

[23]  G. Schneider,et al.  Counting on Natural Products for Drug Design , 2016 .

[24]  Petra Schneider,et al.  Multi-objective molecular de novo design by adaptive fragment prioritization. , 2014, Angewandte Chemie.

[25]  S. Moro,et al.  4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies. , 2006, Journal of medicinal chemistry.

[26]  T. Fujita,et al.  Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity , 1995 .

[27]  T. Fujita,et al.  2-Substituted 2-aminoethanol: Minimum essential structure for immunosuppressive activity of ISP-I (Myriocin) , 1995 .

[28]  R. Reiter,et al.  Cardioprotective Role of Melatonin in Acute Myocardial Infarction , 2020, Frontiers in Physiology.

[29]  S. Rogelj,et al.  Structural simplification of bioactive natural products with multicomponent synthesis. 2. antiproliferative and antitubulin activities of pyrano[3,2-c]pyridones and pyrano[3,2-c]quinolones. , 2008, Journal of medicinal chemistry.

[30]  D. Uemura,et al.  Halichondrins - antitumor polyether macrolides from a marine sponge , 1986 .

[31]  A. Waterson,et al.  Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. , 2011, Bioorganic & medicinal chemistry letters.

[32]  J. Tanaka,et al.  Norhalichondrin A: an antitumor polyether macrolide from a marine sponge , 1985 .

[33]  J. Stowell,et al.  The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells. , 1995, Journal of medicinal chemistry.

[34]  W Patrick Walters,et al.  What do medicinal chemists actually make? A 50-year retrospective. , 2011, Journal of medicinal chemistry.

[35]  A. Saxena,et al.  Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. , 2015, Bioorganic & medicinal chemistry.

[36]  I. Chopra,et al.  Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents , 2005, Antimicrobial Agents and Chemotherapy.

[37]  J. Vederas,et al.  Natural products and their derivatives as tRNA synthetase inhibitors and antimicrobial agents , 2016 .

[38]  C. Niemegeers,et al.  Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide and N-(3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. , 1974, Journal of medicinal chemistry.

[39]  M. Hann,et al.  Finding the sweet spot: the role of nature and nurture in medicinal chemistry , 2012, Nature Reviews Drug Discovery.

[40]  Tiffany L. Kinnibrugh,et al.  Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis. , 2011, Journal of medicinal chemistry.

[41]  D. Hoyer,et al.  SRA880, in vitro characterization of the first non-peptide somatostatin sst1 receptor antagonist , 2004, Neuroscience Letters.

[42]  Guoqiang Dong,et al.  Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections. , 2018, Journal of medicinal chemistry.

[43]  M. Millan N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives , 2005, Psychopharmacology.

[44]  Stefan Wetzel,et al.  Biology-oriented synthesis. , 2011, Angewandte Chemie.

[45]  W. Leonard,et al.  Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development , 1995, Science.

[46]  David W Dodick,et al.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial , 2008, The Lancet.

[47]  Andrew T Maynard,et al.  Quantifying, Visualizing, and Monitoring Lead Optimization. , 2016, Journal of medicinal chemistry.

[48]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[49]  Stefan Wetzel,et al.  Bioactivity-guided mapping and navigation of chemical space. , 2009, Nature chemical biology.

[50]  A. Hyman,et al.  Natural product-inspired cascade synthesis yields modulators of centrosome integrity. , 2012, Nature chemical biology.

[51]  J. McKerrow,et al.  A Cysteine Protease Inhibitor Protects Dogs from Cardiac Damage during Infection by Trypanosoma cruzi , 2005, Antimicrobial Agents and Chemotherapy.

[52]  Craig J. Forsyth,et al.  Total synthesis of halichondrin B and norhalichondrin B , 1992 .

[53]  J. Vacca,et al.  Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility. , 2009, Bioorganic & medicinal chemistry letters.

[54]  Gisbert Schneider,et al.  Scaffold diversity of natural products: inspiration for combinatorial library design. , 2008, Natural product reports.

[55]  J M Liesch,et al.  A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. , 1985, Science.

[56]  J. King,et al.  The Synthesis of Some Fluorene Derivatives1 , 1955 .

[57]  R. S. Ferreira,et al.  Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification. , 2017, Bioorganic & medicinal chemistry.

[58]  K. Scheidt,et al.  Pyrrolidinyl-spirooxindole natural products as inspirations for the development of potential therapeutic agents. , 2007, Angewandte Chemie.

[59]  Herbert Waldmann,et al.  Design of compound libraries based on natural product scaffolds and protein structure similarity clustering (PSSC). , 2005, Molecular bioSystems.

[60]  Zhiyan Xiao,et al.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates , 2016, Medicinal research reviews.

[61]  Martha Donoghue,et al.  Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a “Physician's Choice” Control Arm in a Randomized Approval Trial , 2012, Clinical Cancer Research.

[62]  Herbert Waldmann,et al.  Biology-oriented synthesis: harnessing the power of evolution. , 2014, Journal of the American Chemical Society.

[63]  Herbert Waldmann,et al.  Biology-oriented synthesis of a natural-product inspired oxepane collection yields a small-molecule activator of the Wnt-pathway , 2011, Proceedings of the National Academy of Sciences.

[64]  Herbert Waldmann,et al.  Natural product inspired compound collections: evolutionary principle, chemical synthesis, phenotypic screening, and target identification. , 2017, Drug discovery today. Technologies.

[65]  P. L. McCormack,et al.  Trametinib: First Global Approval , 2013, Drugs.

[66]  James Tsai,et al.  RAF inhibitors that evade paradoxical MAPK pathway activation , 2015, Nature.

[67]  Zongru Guo,et al.  The modification of natural products for medical use , 2016, Acta pharmaceutica Sinica. B.

[68]  Meir Glick,et al.  Construction of a 3D-shaped, natural product like fragment library by fragmentation and diversification of natural products. , 2017, Bioorganic & medicinal chemistry.

[69]  A. Montagnoli,et al.  Cdc7 Inhibition Reveals a p53-Dependent Replication Checkpoint That Is Defective in Cancer Cells , 2004, Cancer Research.

[70]  A. Ziering,et al.  Piperidine derivatives; 1,3-dialkyl-4-aryl-4-acyloxypiperidines. , 1947, The Journal of organic chemistry.

[71]  L. Fan,et al.  Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. , 2005, Journal of pharmacological sciences.

[72]  K D Paull,et al.  Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. , 1991, The Journal of biological chemistry.

[73]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[74]  B. E. Evans,et al.  Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists. , 1987, Journal of medicinal chemistry.

[75]  Lynda Tremblay,et al.  Macrocyclic ketone analogues of halichondrin B. , 2004, Bioorganic & medicinal chemistry letters.

[76]  Alastair J. King,et al.  Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. , 2013, ACS medicinal chemistry letters.

[77]  C. De Virgilio,et al.  Leucyl-tRNA synthetase controls TORC1 via the EGO complex. , 2012, Molecular cell.

[78]  J. Levine,et al.  Synergism between the analgesic actions of morphine and pentazocine , 1988, Pain.

[79]  N-Leucinyl Benzenesulfonamides as Structurally Simplified Leucyl-tRNA Synthetase Inhibitors. , 2018, ACS medicinal chemistry letters.

[80]  M. Hilgers,et al.  Identification of bacteria-selective threonyl-tRNA synthetase substrate inhibitors by structure-based design. , 2013, Journal of medicinal chemistry.

[81]  J. Johnston,et al.  Signaling by IL‐2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency , 1996, Journal of leukocyte biology.

[82]  Stefan Wetzel,et al.  The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification , 2007, J. Chem. Inf. Model..

[83]  Kai Gao,et al.  Theory and applications of differential scanning fluorimetry in early-stage drug discovery , 2020, Biophysical Reviews.

[84]  S. Moro,et al.  The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists. , 2011, Journal of medicinal chemistry.

[85]  A. Schuffenhauer,et al.  Charting biologically relevant chemical space: a structural classification of natural products (SCONP). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[86]  B. E. Evans,et al.  Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[87]  Thomas Böttcher,et al.  An Additive Definition of Molecular Complexity , 2016, J. Chem. Inf. Model..

[88]  José L Medina-Franco,et al.  The many roles of molecular complexity in drug discovery. , 2017, Drug discovery today.

[89]  J. Coyle,et al.  Modulation of N-methyl-D-aspartate receptor function by glycine transport. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[90]  C. Peyssonnaux,et al.  The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.

[91]  N. Oku,et al.  Antiproliferative naphthoquinone esters from Rhinacanthus nasutus Kurz. roots on various cancer cells , 2006 .

[92]  Kyoung Tai No,et al.  Natural products used as a chemical library for protein-protein interaction targeted drug discovery. , 2018, Journal of molecular graphics & modelling.

[93]  S. Moro,et al.  Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study. , 2007, Journal of medicinal chemistry.

[94]  A. Van Aerschot,et al.  Aminoacyl-tRNA synthetase inhibitors as potential antibiotics. , 2011, European journal of medicinal chemistry.

[95]  H. Kosterlitz,et al.  Selectivity of ligands for opioid receptors , 1993 .

[96]  Herbert Waldmann,et al.  Bioactivity-guided navigation of chemical space. , 2010, Accounts of chemical research.

[97]  A. Isacchi,et al.  First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. , 2009, Journal of medicinal chemistry.

[98]  K. Gademann,et al.  Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis , 2016, Angewandte Chemie.

[99]  Jayaraman Chandrasekhar,et al.  Strategies and tactics for optimizing the Hit-to-Lead process and beyond--a computational chemistry perspective. , 2008, Drug discovery today.

[100]  M. Hann Molecular obesity, potency and other addictions in drug discovery , 2011 .

[101]  M. Hines,et al.  Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. , 2010, Journal of medicinal chemistry.

[102]  S. Moro,et al.  The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition. , 2010, Journal of medicinal chemistry.

[103]  J. O’Shea,et al.  Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.

[104]  Brian K. Shoichet,et al.  Increasing Chemical Space Coverage by Combining Empirical and Computational Fragment Screens , 2014, ACS chemical biology.

[105]  T. Okumoto,et al.  Fungal metabolites. Part 14. Novel potent immunosuppressants, mycestericins, produced by Mycelia sterilia. , 1994, The Journal of antibiotics.

[106]  S. Horinouchi,et al.  Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[107]  Pascale Romby,et al.  Structural basis of translational control by Escherichia coli threonyl tRNA synthetase , 2002, Nature Structural Biology.

[108]  Jaroslaw Polanski,et al.  The analysis of the market success of FDA approvals by probing top 100 bestselling drugs , 2016, Journal of Computer-Aided Molecular Design.

[109]  Geng-tao Liu Bicyclol: a novel drug for treating chronic viral hepatitis B and C. , 2009, Medicinal chemistry (Shariqah (United Arab Emirates)).

[110]  C. Ghelardini,et al.  Design, synthesis, and preliminary pharmacological evaluation of 1, 4-diazabicyclo[4.3.0]nonan-9-ones as a new class of highly potent nootropic agents. , 2000, Journal of medicinal chemistry.

[111]  Stefan Wetzel,et al.  Natural-product-derived fragments for fragment-based ligand discovery , 2012, Nature Chemistry.

[112]  T. Steitz,et al.  Insights into editing from an ile-tRNA synthetase structure with tRNAile and mupirocin. , 1999, Science.

[113]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[114]  R. N. Brogden,et al.  Butorphanol: A Review of its Pharmacological Properties and Therapeutic Efficacy , 1978, Drugs.

[115]  F. Giles,et al.  Cdc7 kinase - a new target for drug development. , 2010, European journal of cancer.

[116]  J. Majoral,et al.  Compound high-quality criteria: a new vision to guide the development of drugs, current situation. , 2016, Drug discovery today.

[117]  A. Isacchi,et al.  Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. , 2010, Journal of medicinal chemistry.

[118]  R. Mahajan Bedaquiline: First FDA-approved tuberculosis drug in 40 years , 2013, International journal of applied & basic medical research.

[119]  A. Phillips,et al.  The halichondrins and E7389. , 2009, Chemical reviews.

[120]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[121]  S. Moro,et al.  New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. , 2007, Journal of medicinal chemistry.

[122]  I. Magedov Structural Simplification of Bioactive Natural Products with Multicomponent Synthesis. Part 4. 4H-Pyrano-[2,3-b]naphthoquinones with Anticancer Activity. , 2012 .

[123]  E. Pinard,et al.  Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1. , 2008, Bioorganic & medicinal chemistry letters.

[124]  Melvin J. Yu,et al.  In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. , 2001, Cancer research.

[125]  S. Moro,et al.  2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. , 2009, Journal of medicinal chemistry.

[126]  R. Turnaturi,et al.  (+)-and (-)-Phenazocine enantiomers: Evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects. , 2017, European journal of medicinal chemistry.

[127]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[128]  L. Geng The anti-virus and hepatoprotective effect of bicyclol and its mechanism of action , 2001 .

[129]  S. Van slambrouck,et al.  Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity. , 2012, Bioorganic & medicinal chemistry letters.

[130]  Stefan Wetzel,et al.  Charting, navigating, and populating natural product chemical space for drug discovery. , 2012, Journal of medicinal chemistry.

[131]  L. Eckhardt-Strelau,et al.  Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline , 2015, Science Advances.

[132]  Hui Wen,et al.  Structural Simplification of Bedaquiline: the Discovery of 3‐(4‐(N,N‐Dimethylaminomethyl)phenyl)quinoline‐Derived Antitubercular Lead Compounds , 2016, ChemMedChem.

[133]  Jeremy J. Yang,et al.  Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents. , 2011, Journal of medicinal chemistry.

[134]  D. Hoyer,et al.  Discovery of novel non-peptidic beta-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[135]  Won Kyung Kim,et al.  Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors. , 2016, Bioorganic & medicinal chemistry.

[136]  Michael J. Keiser,et al.  Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors† , 2010, Journal of medicinal chemistry.

[137]  Sunghoon Kim,et al.  Leucyl-tRNA Synthetase Is an Intracellular Leucine Sensor for the mTORC1-Signaling Pathway , 2012, Cell.

[138]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.